Table 2: Comparative analysis of survivor (SG) and non-survivor (NSG) patients after an episode of ATN according to clinical and laboratory characteristics and outcome.

SG (n = 119) NSG (n = 52) P Male gender (%) 61.3 61.5 0.97 Age (years) 56.3 ± 16.1 69.3 ± 12.2 <0.0001 ATN-ISS 0.26 (0.15–0.45) 0.28 (0.19–0.43)   Cardio-vascular disease (%) 37 57.7 0.02 Previous chronic renal disease (%) 37 55.7 0.008 Diabetes (%) 33.6 42.3 0.34 Hypertension (%) 70 69.2   Sepsis (%) 25.6 44.2 0.001 Type of admission (%)        (i) Surgical 32.7 28.8    (ii) No surgical 67.3 71.2   ICU admission (%) 31.9 28.8   SCr baseline (mg/dL) 1 (0.8–1.3) 1.3 (1–1.5) 0.0003 SCr after 12 months 1.3 (1–1.7) 1.6 (1.1–1.9) 0.08 SCr peak (mg/dL) 4.3 (2.6–6.9) 3.7 (2.4–6.4)   ATN etiology (%)        (i) Ischaemic 26.9 39.6    (ii) Nephrotoxic 22.7 18.9    (iii) Mix 23.5 18.9    (iv) Septic 26.9 22.6   ATN severity (%)        (i) Stage I 23.6 25    (ii) Stage II 24.5 28.8    (iii) Stage III 50.9 40.2   Followup (months) 18 (11–44.5) 10.5 (3–20.5) 0.04 Dialysis in-hospital (%) 26.0 17.3 0.20 Recovery of renal function (%) 35.3 36.5 0.83

SCr: serum creatinine. Data showed in %, means ± sd or median (q1–q3).